Metex

Methotrexate, the active ingredient in Metex, is an antimetabolite (folate antagonist) presented as a sterile injectable solution for intramuscular, intravenous, or subcutaneous use. It is employed to manage autoimmune disorders and certain malignancies in adult and pediatric patients.

GNH USA supplies Metex as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, and pharmacies worldwide. The company adheres to stringent quality standards and provides reliable logistics, consistent product availability, and regulatory support across multiple markets.

Methotrexate acts as a folate pathway inhibitor and is indicated for several autoimmune and oncologic conditions.

- Rheumatoid arthritis: reduces disease activity and joint inflammation. - Psoriasis: decreases skin lesions and plaque formation. - Acute lymphoblastic leukemia: impedes leukemic cell proliferation. - Non‑Hodgkin lymphoma: contributes to tumor regression. - Osteosarcoma: used as part of multi‑agent chemotherapy protocols. - Ectopic pregnancy: facilitates resorption of trophoblastic tissue.

Methotrexate may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea and vomiting - Fatigue or weakness - Oral mucositis (mouth sores) - Elevated liver enzymes - Decreased blood cell counts (anemia, leukopenia, thrombocytopenia)

Serious or Rare Side Effects: - Severe hepatotoxicity or liver fibrosis - Pulmonary toxicity (interstitial pneumonitis, fibrosis) - Life‑threatening infections due to immunosuppression - Bone marrow failure (aplastic anemia) - Renal impairment or failure

Before initiating methotrexate therapy, several safety considerations should be observed.

- Pregnancy: contraindicated (Category X); avoid use in women of childbearing potential. - Renal function: assess baseline creatinine and adjust dose if impaired. - Hepatic function: monitor liver enzymes regularly; avoid in pre‑existing severe liver disease. - Hematologic status: perform complete blood counts before and during treatment. - Drug interactions: review concomitant medications for potential additive toxicity. - Store at ambient temperature: keep in original container, protect from light and moisture.

Methotrexate has notable interactions that may require avoidance or close monitoring.

Major Interactions (Avoid): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): increase methotrexate toxicity. - Live vaccines: heightened risk of infection due to immunosuppression. - Trimethoprim‑sulfamethoxazole: additive bone‑marrow suppression.

Moderate Interactions (Monitor Closely): - Proton pump inhibitors: may affect methotrexate renal clearance. - Sulfonamide antibiotics: increase risk of myelosuppression. - Anticonvulsants (e.g., phenytoin): may alter methotrexate metabolism.